These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26092065)

  • 1. Incidence of fracture events with teriparatide: role of study design.
    Hernandez I; Piñera A
    Osteoporos Int; 2015 Aug; 26(8):2219. PubMed ID: 26092065
    [No Abstract]   [Full Text] [Related]  

  • 2. Teriparatide fracture effectiveness in the real world.
    Krege JH; Burge RT; Marin F
    Osteoporos Int; 2015 Aug; 26(8):2217-8. PubMed ID: 25906242
    [No Abstract]   [Full Text] [Related]  

  • 3. Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis.
    Bonafede MM; Shi N; Bower AG; Barron RL; Grauer A; Chandler DB
    Osteoporos Int; 2015 Mar; 26(3):1203-12. PubMed ID: 25567774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
    Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
    Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evidence in the treatment of osteoporosis using weekly teriparatide injections].
    Nakamura Y
    Clin Calcium; 2012 Mar; 22(3):407-13. PubMed ID: 22370308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect and role of teriparatide in the treatment of osteoporosis].
    Nakamura T
    Clin Calcium; 2012 Mar; 22(3):309-14. PubMed ID: 22370296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Once-weekly teriparatide treatment on osteoporosis].
    Nakano T
    Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [To where and until when handle the osteoporosis?].
    Uebelhart B; Ferrari S
    Rev Med Suisse; 2017 Apr; 13(559):859-862. PubMed ID: 28727344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment responses with once-weekly teriparatide therapy for osteoporosis.
    Shiraki M; Ueda S; Sugimoto T; Kuroda T; Nakamura T
    Osteoporos Int; 2016 Oct; 27(10):3057-62. PubMed ID: 27234671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evidence for osteoporosis treatment using PTH (1-34) daily subcutaneous injection].
    Yamamoto T; Hamaya E; Sowa H
    Clin Calcium; 2012 Mar; 22(3):399-406. PubMed ID: 22370307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study.
    Beall DP; Feldman RG; Gordon ML; Gruber BL; Lane JM; Valenzuela G; Yim D; Alam J; Krege JH; Krohn K
    Osteoporos Int; 2016 Mar; 27(3):1191-1198. PubMed ID: 26556737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring the efficacy of once-weekly teriparatide. Are bone turnover markers useful in predicting fracture risk?
    Anagnostis P; Karras SN; Goulis DG
    Curr Med Res Opin; 2014 Jun; 30(6):1177-8. PubMed ID: 24579907
    [No Abstract]   [Full Text] [Related]  

  • 13. Teriparatide and denosumab treatment for pregnancy and lactation-associated osteoporosis with multiple vertebral fractures: A case study.
    Ijuin A; Yoshikata H; Asano R; Tsuburai T; Kikuchi R; Sakakibara H
    Taiwan J Obstet Gynecol; 2017 Dec; 56(6):863-866. PubMed ID: 29241936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Update and perspectives of anabolic therapies for osteoporosis].
    Endo I; Matsumoto T
    Clin Calcium; 2012 Mar; 22(3):327-33. PubMed ID: 22370299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment.
    Gagnon C; Li V; Ebeling PR
    Clin Interv Aging; 2008; 3(4):635-45. PubMed ID: 19281056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teriparatide persistence and tolerance in patients with osteoporosis: Observational data from clinical practice.
    Taisne N; Mignot MA; Legroux I; Cortet B; Paccou J
    Joint Bone Spine; 2018 Oct; 85(5):641-642. PubMed ID: 29407040
    [No Abstract]   [Full Text] [Related]  

  • 17. [Monitoring bone turnover markers during treatment with the anabolic agent teriparatide; in particular, treatment using daily and weekly subucutaneous injections].
    Miyauchi A
    Clin Calcium; 2012 Mar; 22(3):387-98. PubMed ID: 22370306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for Use of Teriparatide in Spinal Fusion Surgery in Osteoporotic Patients.
    Chaudhary N; Lee JS; Wu JY; Tharin S
    World Neurosurg; 2017 Apr; 100():551-556. PubMed ID: 27923758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Teriparatide: human recombinant parathyroid hormone (1-34) as a daily subcutaneous injection].
    Sowa H; Hamaya E; Yamamoto T
    Clin Calcium; 2011 Jan; 21(1):9-16. PubMed ID: 21187589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
    Mok J; Brown C; Moore AEB; Min SS; Hampson G
    Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.